FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2776-2786 June 26, 2008 Number 26 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Lohrmann, J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.

Methods In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The primary efficacy outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. Secondary efficacy outcomes included major venous thromboembolism (i.e., proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism) and symptomatic venous thromboembolism. The primary safety outcome was major bleeding.

Results The primary efficacy outcome occurred in 79 of 824 patients (9.6%) who received rivaroxaban and in 166 of 878 (18.9%) who received enoxaparin (absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P<0.001). Major venous thromboembolism occurred in 9 of 908 patients (1.0%) given rivaroxaban and 24 of 925 (2.6%) given enoxaparin (absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P=0.01). Symptomatic events occurred less frequently with rivaroxaban than with enoxaparin (P=0.005). Major bleeding occurred in 0.6% of patients in the rivaroxaban group and 0.5% of patients in the enoxaparin group. The incidence of drug-related adverse events, mainly gastrointestinal, was 12.0% in the rivaroxaban group and 13.0% in the enoxaparin group.

Conclusions Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894 [ClinicalTrials.gov] .)

Source Information

From Nordsjællands Hospital, Hørsholm, Denmark (M.R.L.); University of Insubria, Varese, Italy (W.A.); Aarhus University Hospital, Aarhus, Denmark (L.C.B.); Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington (J.R.L.); Paris Descartes University, Cochin Hospital, Paris (N.R.); Bayer HealthCare, Wuppertal, Germany (T.J.B., F.M.); and McMaster University, Hamilton, ON, Canada (A.G.G.T.).

Address reprint requests to Dr. Lassen at the Department of Orthopedic Surgery, Nordsjællands Hospital, Usserd Kongevej 102, DK-2970 Hørsholm, Denmark, or at mirula{at}noh.regionh.dk.

Full Text of this Article

Related Letters:

Rivaroxaban for Thromboprophylaxis
Schuman E. P., Lippi G., Franchini M., Targher G., Lotke P. A., ten Cate H., Hamulyak K., Geerts W., the RECORD 1 and RECORD 3 Investigators , Lassen M. R., Ageno W., Turpie A. G.G., Lohrmann J., Becker R. C.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:2174-2176, Nov 13, 2008. Correspondence

This article has been cited by other articles:

• Schulman, S. (2009). Rivaroxaban in Orthopedic Surgery -- A Change of Paradigm?. CLIN APPL THROMB HEMOST 15: 613-620 [Abstract]  
• Levine, M. N. (2009). New Antithrombotic Drugs: Potential for Use in Oncology. JCO 27: 4912-4918 [Abstract] [Full Text]  
• (2009). Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban. DTB 47: 116-120 [Abstract] [Full Text]  
• Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., Portman, R. J. (2009). Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. NEJM 361: 594-604 [Abstract] [Full Text]  
• Van Thiel, D., Kalodiki, E., Wahi, R., Litinas, E., Haque, W., Rao, G. (2009). Interpretation of Benefit-Risk of Enoxaparin as Comparator in the RECORD Program: Rivaroxaban Oral Tablets (10 milligrams) for Use in Prophylaxis in Deep Vein Thrombosis and Pulmonary Embolism in Patients Undergoing Hip or Knee Replacement Surgery. CLIN APPL THROMB HEMOST 15: 389-394 [Abstract]  
• Hull, R. D., Yusen, R. D., Bergqvist, D. (2009). State-of-the-Art Review: Assessing the Safety Profiles of New Anticoagulants for Major Orthopedic Surgery Thromboprophylaxis. CLIN APPL THROMB HEMOST 15: 377-388 [Abstract]  
• Rajesparan, K., Biant, L. C., Ahmad, M., Field, R. E. (2009). The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br 91-B: 776-783 [Abstract] [Full Text]  
• Rea, C., Hunt, B. J (2009). Reducing vascular risk - venous thromboembolism and anticoagulation. Clin Risk 15: 90-92 [Full Text]  
• Eriksson, B. I., Kakkar, A. K., Turpie, A. G. G., Gent, M., Bandel, T.-J., Homering, M., Misselwitz, F., Lassen, M. R. (2009). Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 91-B: 636-644 [Abstract] [Full Text]  
• Streiff, M. B., Haut, E. R. (2009). The CMS Ruling on Venous Thromboembolism After Total Knee or Hip Arthroplasty: Weighing Risks and Benefits. JAMA 301: 1063-1065 [Full Text]  
• Eikelboom, J. W., Karthikeyan, G., Fagel, N., Hirsh, J. (2009). American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ: What Are the Implications for Clinicians and Patients?. Chest 135: 513-520 [Abstract] [Full Text]  
• Turpie, A. G., Bauer, K. A., Davidson, B., Gent, M., Kwong, L., Lassen, M. R., Cushner, F., Lotke, P., Berkowitz, S. D., Bandel, T. J., Misselwitz, F., Fisher, W. (2008). Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. ASH ANNUAL MEETING ABSTRACTS 112: 35-35 [Abstract]  
• Schuman, E. P., Lippi, G., Franchini, M., Targher, G., Lotke, P. A., ten Cate, H., Hamulyak, K., Geerts, W., the RECORD 1 and RECORD 3 Investigators, , Lassen, M. R., Ageno, W., Turpie, A. G.G., Lohrmann, J., Becker, R. C. (2008). Rivaroxaban for Thromboprophylaxis. NEJM 359: 2174-2176 [Full Text]  
• Camporese, G., Noventa, F., Bernardi, E. (2008). Is Low-Molecular-Weight Heparin Suitable in All Patients Undergoing Knee Arthroplasty?. ANN INTERN MED 149: 687-688 [Full Text]  
• Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., Segers, A., on behalf of the Einstein-DVT Dose-Ranging Study i, (2008). A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112: 2242-2247 [Abstract] [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 337: a582-a582 [Full Text]  
• (2008). Rivaroxaban Is Superior to Enoxaparin for Thromboprophylaxis After Knee and Hip Arthroplasty. JWatch General 2008: 1-1 [Full Text]  
• Lohrmann, J., Becker, R. C. (2008). New Anticoagulants -- The Path from Discovery to Clinical Practice. NEJM 358: 2827-2829 [Full Text]  
• (2008). Rivaroxaban for Thromboprophylaxis After Joint Replacement. JWatch Oncology and Hematology 2008: 1-1 [Full Text]  
• Francis, C. W. (2008). New Issues in Oral Anticoagulants. ASH Education Book 2008: 259-265 [Abstract] [Full Text]